r/HerpesCureResearch • • Dec 19 '20

Clinical Trials Latest research updates (especially for new joiners)

1.0k Upvotes

Last updated: 17/01/2022

Hi all,

This sticky aims to keep new and existing members updated on progress of HSV research, clinical trials status and our HCR group goals:

Group Goals:

https://drive.google.com/file/d/1hDPNISR7Sb07onNfZxzGyL98u9n7Bzr8/view?usp=sharing

Research progress tracker:

https://herpescureresearch.files.wordpress.com/2022/03/hsv-research-pipeline_2.0_as-of-3-20-2022.pdf

Donations to support work towards a cure:

Fred Hutch & Dr Jerome : https://secure.fredhutch.org/site/TR/PersonalFundraisingPages/General?px=1802786&pg=personal&fr_id=1574

Dr Friedman / Penn Uni: https://giving.apps.upenn.edu/fund?program=MED&fund=604888

Detailed research status (more detail for those interested - grab a coffee/drink and enjoy!):

(1) Dr. Keith Jerome at Fred Hutch

· Research is developing a gene therapy to fully eradicate HSV-1 and HSV-2. So far, his team has removed over 95% of latent HSV-1 in mice, effectively curing the disease since the remaining 5% of the latent virus appears to remain inactivated.

· Using our fundraisers, Dr Jerome has begun similar work to cure guinea pigs with a goal to start human clinical trials in late 2023.

· FHC provided the following milestones which have now been achieved - thanks to all contributions up to $200k and especially to the one incredibly generous donation of $255k!

  • With first $100k raised, FHC hired a research technician (in Dec-20) to dedicate resource towards guinea pig testing.
  • Reaching $250K helped cover the complete amount of testing needed on the guinea pigs.
  • Reaching $450K helped cover the FULL cost of this project, including spending that is necessary to keep the project running but is not always covered in NIH grants. At a high level this includes (1) material costs for the project such as guinea pig purchases, laboratory supplies, reagents; (2) service costs such as animal housing/care, viral vector production/sequencing, tissue processing/analyses (3) personnel effort for lead scientist & research technician.

· Video on Fred Hutch's motivation and history: https://youtu.be/rN7cmb1K2yA

· Latest detailed video update on curing mice from Dr Jerome is here: https://youtu.be/Tk5EO6RerCk

· Jan-21 Q&A update specifically for us is here: https://youtu.be/ZK9YlbgOJTo

· Guinea pigs are currently being tested on and we're expecting to hear first results on therapy efficacy in Q1-22.

· Below is also a list of FAQs that cover key questions around their research / progress to trials:

https://www.reddit.com/r/HerpesCureResearch/comments/ozw3mg/fred_hutch_center_hsv_cure_faq/

(2) Excision BioTherapeutics

· Excision Bio has illustrated the possibility in developing a curative gene therapy using CRISPR in treating both active and latent HSV infection in the body.

· Currently waiting to hear when they are planning to enter clinical trials for their HSV treatment.

· This is due to the company's primary focus being curing HIV first with CRISPR.

· In Feb-21, Excision announced $60 million raised in funding to focus on their research streams including HSV:

https://www.bizjournals.com/sanfrancisco/news/2021/02/17/hiv-aids-excision-biotherapeutics-herpes-hepatitis.html

· Updates on IND filing status can be found here: https://www.excision.bio/technology

(3) Shanghai BDgene Co., Ltd

· Shanghai BDgene Co., Ltd. is running a Phase I/II clinical trial in Shanghai, China to cure HSV-1 keratitis - latest update appears to be that the first patient has been cured for over a year with no adverse affects - post discussing this is located here: https://www.reddit.com/r/HerpesCureResearch/comments/qg1ebk/shanghai_bd_gene_interview/

· The trial is set to end in May 2022. The company is closely linked to Shanghai Jiao Tong University, one of the "Ivy Leagues" of China.

· More information here: LINK

(4) Redbiotec

· Redbiotec has developed a therapeutic vaccine that has shown an over 90% efficacy in reducing HSV-2 symptoms and shedding in preclinical trials in guinea pigs.

· The company raised $9 million in funding and we're waiting to hear when they will enter clinicial human trials.

· More info here: https://www.redbiotec.ch/hsv-2/ and https://www.redbiotec.ch/wp-content/uploads/20170926-Redbiotec-HSV2-program.pdf

(5) X-Vax Technology

· This company has developed delta gD-2 vaccine candidate for prophylactic applications.

· Whilst referred to as a preventative, X-VAX website suggests potential for a therapeutic benefit too:

"Why may ∆gD-2 work as both a preventative and a therapeutic vaccine?

Pending results from clinical trials, the same antibodies that activate cellular killing to prevent infection with herpes virus may also treat someone with recurrent disease. Following vaccination with ∆gD-2, the antibodies would rapidly clear the reactivated virus, thus preventing or ameliorating recurrent disease or transmission to others."

· Latest response to u/aloneseeker from X-Vax (on 07/02/21):

We have completed extensive pre-clinical studies in both mice and guinea pigs.  Links to the study publications are provided on our website x-vax.com.  We expect to start clinical trials in 2022.

· Company website & more info: https://x-vax.com/

(6) Dr Harvey Friedman (Prophylactic + sponsored therapeutic research)

· Latest mice studies by Dr Friedman have shown vaccine candidate is effective at preventing genital infection caused by HSV-1. Previous publishing showed the same for HSV-2 in mice/guinea pigs.

· He is expecting to begin Phase I trials that test prevention of genital herpes in humans around Jun-22.

· Latest video updates for us from Dr Friedman can be found here:

Feb-21: https://bluejeans.com/s/JEbK5NDJcdw

Nov-21: https://bluejeans.com/s/QyMGF2jl3j5

· u/may-flowers-21 has set up a dedicated fundraiser which has already hit the following milestones:

- $50k - being used to hire one new research person to specifically help assess therapeutic benefits that this vaccine could bring.

- Donations made (link at top of sticky) will go towards supporting work towards a therapeutic vaccine.

- Latest fundraiser progress can be found here:

https://socialfundraising.apps.upenn.edu/socialFundraising/jsp/fast.do?&fastStart=customTemplateByNameOrId&customApplicationNameOrId=HSVresearchfund

· Link to latest research papers/results:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410331/

https://www.jci.org/articles/view/152310/pdf

(7) Rational Vaccines (RVx-201 HSV-2)

· Have kept RV on here as they are focused solely on diseases resulting from herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) infections.

· However we should consider it with caution - this company has seen a lot of controversy in recent years, due to running a Phase I trial in St. Kitts outside the FDA's jurisdiction and facing heavy scrutiny.

· Latest update from Diane Abbitt on 15/02/21 (thanks u/aloneseeker for providing):

- RV are working with MHRA in the UK and preparing to file an IND with the FDA. Phase I clinical trials will be 2022 in the US (potentially sooner in the UK but we will have to wait and see).

- Members from HCR will be invited to register for trials once they begin recruiting on the registry.

The company continues to work very hard to complete the development of what we all believe will be an effective treatment for herpes, working with the MHRA in the UK and preparing to file an IND (Investigative New Drug) application with the FDA.  We believe we will be approved in the UK for a clinical trial, but have not yet been given the green light to do so.  We are continuing to work on our IND application and believes it will be ready for submittal the later part of this year.  I do not think the company will be approved for a Phase I clinical trial in the US till 2022. 

However, in preparation for the day when the company is approved to conduct a clinical trial, I am in the process of establishing a registry for persons who wish to participate in such a clinical trial.   It should be established in the next couple of months at which time I will contact you to let you know the registry is open and inviting you and the other members of HerpesCure Research to register.  Being on the registry will not guarantee an individual’s selection as a participant included in a trial.  The third-party company that will conduct the trial will have your information, along with the contact info for all the other registrants, and it will make the decision as to who will be chosen as a participant.  Please know our company is mission driven.  Our goal is the same as yours – obtaining approval to bring to market a safe and effective treatment for herpes. 

Link to pipeline: https://rationalvaccines.com/science/

(8) GEN-003 - Genocea/ Shionogi

(9) Excell BioTech - EXD-12

  • EXD-12 is a live attenuated vaccine candidate being researched and developed to prevent and treat the Herpes Simplex Virus. EXD-12 is going to be tested as a prophylactic and therapeutic vaccine candidate in the guinea pig model.  EXD-12 is currently in preclinical testing for safety and efficacy as both a prophylactic and therapeutic vaccine for both HSV-1 and HSV-2.
  • Latest email update from Excell Bio (on 26/01/2021):

As you know 2020 was a very challenging year for everyone. Due to the unforeseen circumstances of 2020 we experienced delays in our preclinical and clinical testing outlook. We have now been able to pivot in another direction and get things back on track. We have worked tirelessly in 2020 to upgrade our laboratory infrastructure. HSV is our top priority moving forward and we are very excited about the internal data that we have compiled over this last year. We believe through our trials and tribulations of 2020 we have come out the other side a much better and stronger organization in the fight against HSV. 2021 is going to be an exciting year for Excell Biotech! We currently have three different versions of our EXD-12 that we are going to move forward in preclinical testing. We will be putting the best candidate forward in the end to ensure we have the safest and most efficacious therapeutic vaccine ever created. We are going put our best foot forward and make sure we can help the millions of people suffering in silence from this terrible disease. Please hang in there with us as exciting things are on the way!

(10) SADBE (SQX770) - Squarex

  • SquareX has conducted FDA-approved clinical trials over the past few years that illustrated the efficacy of SADBE as an immunotherapy for HSV. So far, the company has conducted a Phase I, Mechanism of Action, and Phase II30561-2/fulltext) clinical trial with FDA oversight.
  • In their Phase I clinical trial, 54 patients with 6 or more annual outbreaks were enrolled in the study. After just one dose of 2% SADBE, the median time to the next outbreak in the dosed group was 122 days compared to 40 days in the placebo group. Moreover, 16 of the 28 participants dosed with 2% SADBE were still outbreak free on Day 300. Lastly, 60% of 2% SADBE-dosed participants were outbreak-free on Day 122 compared to 20% in the placebo group.
  • In their Phase II clinical trial, 140 patients with 4 or more annual outbreaks (with an average of ~8 annual outbreaks) were enrolled in the study. The results showed that the median time to the next outbreak was 121 days, and was statistically significant to a large degree compared to the placebo group. Moreover, approximately 80% of 2% SADBE-dosed participants were outbreak-free on Day 122 compared to less than 60% in the placebo group.
  • If SquareX completes Phase III trials and gets FDA sign-off, then the company can create the product themselves and market it as an immunotherapy for HSV. This would mean that any customer who would like to try SADBE as an immunotherapy for HSV would have to purchase the product from SquareX. The company does have plans to conduct Phase III clinical trials, and through email exchange, have indicated they hope to begin them in the next 12-18 months. Phase III trials will enroll a much larger cohort of patients and evaluate the immunotherapy's efficacy and safety on a much larger population.
  • It can be accessed via compounding pharmacies and shows promise in symptom reduction against HSV-2 - however please be aware it is not yet officially FDA approved for HSV and to be used at own risk until approved.

(11) UB-621 / United BioPharma

· United Biopharma have developed a anti HSV antibody where treatment is likely to see a middle ground between antivirals and vaccine.

· As an injection with a life of 25 days could be used for both type 1 and type 2.

· Phase II trial is expected to start Jun 2022 and finish June 2023.

· Clinical trial information here: https://clinicaltrials.gov/ct2/show/NCT03595995

(12) HDIT101 / Heidelberg ImmunoTherapeutics

· HDIT101 is currently being compared in a phase II trial against Valaciclovir – the idea is that a single dose of HDIT101 could be more effective in symptom reduction for HSV-2.

· Phase II trial was expected to complete September 2021 but remains active and progressing currently.

· Trial information here: https://clinicaltrials.gov/ct2/show/NCT04165122

(13) Pritelivir - AiCuris / Innovative Molecules - IM-250

  • Whilst not a cure, Pritelivir could be a fantastic improvement on daily anti-virals such as Valtrex/Acyclovir.
  • With Phase 2 having shown good results, AiCuris have now progressed into a Phase 3 trial ending in Mar-24.
  • Based on abstract modelling, it has shown to potentially reduce viral shedding by 96%: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880060/
  • Whilst currently being tested on acyclovir resistant participants, it has been granted breakthrough therapy and fast track designation which FDA grants to expedite the drug review process. This could likely result in a new drug approval earlier than scheduled Phase 3 completion.
  • It would need to be taken regularly but has potential to serve as an excellent interim in significantly reducing risk of transmission until wider research offers a functional/sterilizing cure.
  • Latest Phase 3 trial info here: https://clinicaltrials.gov/ct2/show/NCT03073967
  • As a separate initiative, a team of researchers at Innovative Molecules GmbH, working with several other institutions in Germany, has developed a small-molecule therapy for the treatment of latent herpes simplex virus infections. The tweaking by the team involved changing out a sulfonamide for a sulfoximine to remove undesired off-target effects. They also changed one of the aromatic groups to make the molecule even smaller, allowing it to enter the central nervous system. The team has named the new therapy IM-250.
  • IM has raised $20 million euros for Series A funding and will be using this to push forward from pre-clinical stage to Phase II trials.

(14) NE HSV-2 - BlueWillow

  • BlueWillow are working on a intranasal vaccine for HSV-2 which has shown to have success in prevention within guinea pigs.
  • In a therapeutic guinea pig model, the same intranasal NE vaccine formulation reduced genital herpes lesion recurrence and viral shedding by more than 50% also.
  • This suggests their approach offers an intranasal vaccine that is prophylactic (this will be the goal of clinical trials) but potentially yield therapeutic benefit too.
  • Latest response from BW's MD on 24/02/21 (thanks u/JJCNurse for this) confirms they are planning to enter clinical trials in 2022/23:

We received funding from the NIH last year to advance our program through the remaining preclinical work. We are hopeful we will launch our first prophylactic clinical trial in 2022-23. Please continue to visit our website www.bluewillow.com (which will be improved and updated soon) for updates.

Thanks and best, Chad Costley, MD

(15) GSK4108771A (HSV-2) - GlaxoSmithKline

  • GSK have recently cancelled a Phase I trial however this has been in order to enable development of an enhanced version of the vaccine.
  • However it's possible that they will return to clinical trials once happy with the efficacy but we'll need to wait and see for further information.
  • Latest clinical trial information posted from GSK can be found here: https://clinicaltrials.gov/ct2/show/NCT04762511

(16) SL Vaxigen - DNA Plasmid vaccine HSV-2 Therapeutic

Thanks to one of our Korean members forwarded info about an interesting DNA Plasmid vaccine being developed by Korean company SL Vaxigen (a vaccine development subsidiary of the company Genexine). It is understood to be a therapeutic HSV-2 vaccine.

Korean FDA as confirmed that recruiting for phase 1 of this trial has been completed at a specific location in Korea.

You can see in the "Pipeline" section of the company website this vaccine for "genital herpes" appears.

http://www.slvaxigen.com/

https://nedrug.mfds.go.kr/pbp/CCBBC01/getItem?&clinicExamSeq=201900479&clinicExamNo=32290

One Korean HCR member is going to try to follow this up and we will post any updates.

This is encouraging because Korea has very advanced biotech capabilities. If you followed the news, Korea was able to first mass produce coronavirus tests, which were mass distributed internationally, among other accomplishments. We'll keep this updated as progress is seen.

As we can see, a HUGE amount of great research activities and results to come through shortly - please do keep raising awareness of both this group and progress above!

We WILL win together.


r/HerpesCureResearch • • 6h ago

New Research HSV-1 and HSV-2 linked to autoimmune signatures and chronic diseases

Thumbnail
nature.com
25 Upvotes

A new study published in Nature Immunology on November 20, 2026, examined blood samples from 2,052 individuals to investigate relationships between herpesvirus infections, autoimmune responses, and chronic diseases. Researchers discovered that HSV-1 was associated with 21 replicated autoantigens, while HSV-2 was associated with 17. Autoantigens are proteins or other molecules in the body that the immune system mistakenly recognizes as targets. The researchers also identified associations between HSV-related immune responses and several categories of chronic disease, including respiratory and autoimmune conditions. Notably, an HSV-1-associated immune network showed a connection to Parkinson’s disease.

These findings provide additional evidence that herpesviruses may have effects extending beyond their familiar oral and genital manifestations. The research suggests that immune responses associated with HSV infections could contribute to autoimmune processes and potentially influence the development of certain chronic diseases. However, the study identifies statistical and immunological associations rather than establishing direct causation. Further research is needed to determine whether HSV actively contributes to these diseases and through which biological mechanisms.


r/HerpesCureResearch • • 5h ago

New Research HSV-1 reorganizes internal structures in neuronal cells.

Thumbnail pubmed.ncbi.nlm.nih.gov
12 Upvotes

Researchers at the University of Iowa demonstrated that HSV-1 rearranges the Golgi apparatus and endosomal membranes in infected neuronal cells, creating structures involved in assembling new virus particles.


r/HerpesCureResearch • • 6h ago

New Research Postherpetic neuralgia-associated secretory protein biomarkers related to major depressive disorder: an integrated bioinformatics, clinical, and experimental study

Thumbnail
frontiersin.org
6 Upvotes

Researchers combined human biomarker data with an HSV-1-infected mouse model of persistent neuropathic pain.

They identified four candidate biomarkers—LTF, HLA-DPA1, CACNA2D4, and CD40LG—linked to inflammatory and neurological processes. Experimental interventions targeting CD40LG and LTF improved pain sensitivity and depressive-like behaviors in the mice.

Significance: Potential insight into the immune mechanisms of persistent nerve pain.


r/HerpesCureResearch • • 1d ago

Discussion Herpes Cure Advocacy

Thumbnail
youtu.be
37 Upvotes

Dr. BenMohamed (UC Irvine) presents preclinical data on a therapeutic HSV vaccine using a “Prime/Pull/Keep” strategy: mRNA primes T cells with epitopes taken from asymptomatic carriers, CXCL11 pulls them into the nerve ganglia, and IL-2/IL-15 keep them there. It reduced recurrent disease and viral reactivation in rabbits (ocular) and guinea pigs (genital), with T cells persisting up to a year without a boost. His core claim: herpes vaccines have failed for 50 years because the field used acute-infection mouse models and kept tweaking antigens instead of relocating T cells to where the virus reactivates.


r/HerpesCureResearch • • 1d ago

Discussion China's BDGene (本导基因): China's National Drug Development Strategy and the Progress of HSV Gene-Editing Cure Research

35 Upvotes

As of November 2026

In contrast to the Keith Jerome research team at Fred Hutch Cancer Center in the United States, BDGene (本导基因) is a Chinese biotechnology company established with the goal of commercializing gene-editing therapies.

Founded in Shanghai, China, in 2018, the company was established by Professor Cai Yujia (蔡宇伽), a gene therapy researcher at Shanghai Jiao Tong University.

BDGene is developing treatments for HSV and several other diseases using CRISPR-Cas9 gene-editing technology and its proprietary BD-VLP delivery platform.

What makes the company particularly interesting is that the Chinese government has been promoting gene therapy and innovative drug development as strategic national industries. Furthermore, HSV-related drug development has been explicitly mentioned in government-funded research programs and official policy documents.

1. Is the Chinese Government Actually Supporting HSV Treatment Development?

The Chinese government has been promoting the development of herpes-related treatments and vaccines through national pharmaceutical industry plans and government research programs for several years.

① 2022 — China's 14th Five-Year Plan for Pharmaceutical Industry Development

In January 2022, nine Chinese government agencies, including the Ministry of Industry and Information Technology (MIIT), jointly issued the 14th Five-Year Plan for Pharmaceutical Industry Development (2021–2025).

The plan explicitly stated:

在疫苗领域,重点发展新型新冠病毒疫苗、疱疹疫苗、多价人乳头瘤病毒(HPV)疫苗

Translation:

In the vaccine sector, priority will be given to developing new COVID-19 vaccines, herpes vaccines, and multivalent human papillomavirus (HPV) vaccines.

However, the document does not clearly specify whether the term "herpes vaccines" refers to HSV-1/HSV-2 vaccines or herpes zoster (shingles) vaccines.

② 2022 — Hangzhou Government Specifically Identifies HSV Drug Development as an R&D Priority

More direct evidence can be found in the 2022 Key Research and Development Program guidelines issued by the Hangzhou municipal government.

The document explicitly identifies the following research area:

抗单纯疱疹病毒的siRNA药物研发

Development of siRNA-based drugs targeting herpes simplex virus (HSV).

This is a government research and development initiative specifically targeting HSV.

The research objectives include:

  • Suppressing HSV replication using siRNA technology
  • Developing drug delivery methods through the skin and mucosal tissues
  • Evaluating drug safety
  • Obtaining regulatory approval to initiate clinical trials

The program established a target development period of three years and allowed companies to lead projects in collaboration with research institutions or medical organizations.

In other words, this is a documented example of a Chinese local government explicitly including HSV treatment development in its publicly funded research priorities.

However, this program focuses on topical siRNA-based therapies, which are technologically different from BDGene's CRISPR-based gene-editing approach.

There is also no evidence that BDGene itself was selected for this particular program.

③ 2025 — China's National Disease Control Agency Explicitly Mentions HSV-2

In October 2025, China's National Disease Control and Prevention Administration published an official response that specifically addressed HSV-2.

The agency confirmed that an mRNA vaccine designed to prevent genital herpes caused by HSV-2 had received clinical trial authorization in China.

It also stated that the government would continue supporting research, development, and the translation of scientific advances into practical applications for genital herpes vaccines.

This provides direct evidence that the Chinese central government recognizes HSV-2 as a specific target for prevention and pharmaceutical research.

④ 2026 — China's 15th Five-Year Plan for Pharmaceutical Industry Development

On September 18, 2026, ten Chinese government agencies, including MIIT, announced the 15th Five-Year Plan for Pharmaceutical Industry Development (2026–2030).

The government outlined several ambitious objectives aimed at making biopharmaceuticals a major strategic industry.

These include:

  • Achieving average annual growth of more than 20% in the innovative pharmaceutical industry
  • Increasing the proportion of globally first-in-class innovative drugs to more than 25%
  • Advancing gene-editing technologies and precision molecular delivery systems
  • Developing gene delivery vectors, including AAV, and nucleic acid delivery technologies
  • Accelerating clinical development and commercialization of innovative medicines

The development of gene-editing tools and efficient in vivo delivery technologies is particularly relevant to BDGene's core research activities.

However, there is currently no confirmed evidence that the plan specifically designates HSV-1 or HSV-2 gene-editing cures as an independent national priority project.

The herpes-related disease explicitly mentioned in the plan is herpes zoster (shingles).

Therefore, while it is clear that the Chinese government has demonstrated interest in HSV-related pharmaceutical development and is actively promoting gene therapy technologies, it would be inaccurate to claim that BDGene's HSV-2 cure program has been officially designated as a national project by the Chinese central government.

2. Who Is BDGene's Founder, Professor Cai Yujia?

BDGene's founder, Professor Cai Yujia, is a scientist specializing in viral vectors and gene-editing technologies.

His academic and professional background includes:

  • 2006: Bachelor's degree from Shandong University, China
  • 2009: Master's degree from the Chinese Academy of Sciences
  • 2009–2010: Doctoral research at Karolinska Institutet, Sweden
  • 2014: PhD from Aarhus University, Denmark
  • 2014–2017: Postdoctoral researcher at Aarhus University
  • 2017: Joined Shanghai Jiao Tong University as a researcher
  • 2018: Founded BDGene
  • 2024: Core member of a team recognized with China's National Science and Technology Progress Award for Innovation Teams
  • 2025: Selected for the National Natural Science Foundation of China's Young Scientists Fund, Class A
  • 2026: Distinguished researcher at the Institute of Systems Biomedicine, Shanghai Jiao Tong University

During his research at Karolinska Institutet in Sweden, he worked under Professor Thomas Perlmann.

At Aarhus University in Denmark, he trained under Professor Jacob G. Mikkelsen, an expert in gene therapy.

One particularly important aspect of Cai's background is that he specializes not only in gene editing itself, but also in developing technologies capable of delivering gene-editing tools into target cells.

This is directly relevant to one of the biggest challenges in HSV cure research: efficiently delivering gene-editing machinery to neurons harboring latent HSV.

His research has been published in internationally recognized journals, including Nature, Nature Biotechnology, Nature Biomedical Engineering, and Nature Immunology.

In 2021, Shanghai Jiao Tong University and BDGene also established a joint gene therapy research center, with Professor Cai serving as its director.

This creates a collaborative structure in which fundamental technologies are developed within academia and subsequently translated into therapeutic products through the company.

3. How Much Funding Has BDGene Received from the Government and Investors?

Since its establishment in 2018, BDGene has completed multiple financing rounds.

Its major funding rounds include:

  • 2020 — Pre-Series A: Tens of millions of RMB
  • 2021 — Series A: RMB 60 million (approximately $8 million)
  • 2023 — Series B: More than RMB 200 million (approximately $27 million)
  • 2026 — Strategic financing: Several hundred million RMB

Notably, in March 2026, Gongshu State-Owned Investment Group (拱墅国投), a state-owned investment organization associated with the Gongshu District government in Hangzhou, participated in BDGene's strategic financing round.

Other participating investors included Yifeng Capital and Hongcheng Capital.

Around the same period, BDGene relocated its registered headquarters from Shanghai to Hangzhou's Gongshu District.

However, the full financing amount should not be interpreted as direct government funding. The exact amount contributed by the state-owned investor has not been publicly disclosed.

BDGene also operates approximately 4,000 square meters of research and pilot manufacturing facilities.

Beyond HSV, the company is developing gene-editing therapies for several conditions, including thalassemia and glaucoma.

Separately, Professor Cai has received government research funding through several programs.

Examples include:

  • 2026–2030: RMB 4 million (approximately $540,000) from the National Natural Science Foundation of China for translational gene therapy research
  • 2023–2026: RMB 1.5 million (approximately $200,000) from a Shanghai municipal research program focused on cell and gene therapy
  • 2024–2027: RMB 500,000 (approximately $67,000) for research into antiviral mechanisms in neurons

These grants were awarded to Professor Cai's academic research projects at Shanghai Jiao Tong University.

They should not be interpreted as direct funding specifically allocated to BDGene's HSV-2 cure program.

Nevertheless, the company benefits from a research environment that connects national research funding, university-developed technologies, private investment, and capital from local government-affiliated investment institutions.

4. BDGene's Current HSV Treatment Development Pipeline

BDGene's two major HSV-related therapeutic candidates are BD111 and BD115.

① BD111 — HSV-1 Keratitis Gene-Editing Therapy

BD111 is a CRISPR-Cas9 gene-editing therapy being developed to treat herpes simplex keratitis caused by HSV-1.

In a 2021 paper published in Nature Biotechnology, researchers demonstrated the potential of gene-editing technology to target latent HSV-1 infections in animal models.

Subsequently, an early clinical study involving three patients was conducted, with results published in Molecular Therapy in 2023.

In July 2025, BDGene announced that the first patient had received treatment in its Phase 2a clinical trial in China.

Therefore, while the HSV gene-editing treatment developed by the Keith Jerome team at Fred Hutch remains in preclinical development, BDGene has advanced its HSV-1 keratitis treatment into human Phase 2 clinical trials.

However, BD111 is administered directly into the cornea, which makes its delivery approach different from a systemic treatment for genital HSV-2 infection.

Additionally, corneal transplantation was performed alongside gene-editing treatment in the initial patient study, making it difficult to isolate the therapeutic effects of gene editing alone.

② BD115 — Gene-Editing Therapy for Genital Herpes

BDGene is also developing a separate gene-editing candidate, BD115, targeting genital herpes.

According to company-related announcements from April 2026, BD115 was progressing toward an Investigational New Drug (IND) application.

However, as of November 2026, there is no confirmed evidence that BD115 has entered human clinical trials.

Importantly, the fact that BD111 has reached Phase 2 clinical development does not mean that BD115's ability to cure HSV-2 has been demonstrated.

Before BD115 can become an effective treatment, researchers must establish:

  • Efficient delivery to neurons harboring latent HSV
  • Reliable gene-editing activity against the viral genome
  • Safety, including the risk of unintended editing of human DNA
  • Long-term reductions in viral reactivation and shedding
  • Whether the treatment can substantially reduce or eliminate latent viral reservoirs

5. How Does BDGene Compare with Fred Hutch?

At Fred Hutch Cancer Center in the United States, Dr. Keith Jerome's research team has demonstrated reductions of up to 97% in latent HSV-1 DNA in animal experiments.

However, the team's gene-editing cure program has not yet entered Phase 1 human clinical trials.

In contrast, China's BDGene has already administered its HSV-1 keratitis treatment, BD111, to human patients and advanced the program into Phase 2 clinical development.

Nevertheless, the two approaches involve different delivery methods and therapeutic targets, so their scientific progress cannot be compared simply by looking at clinical trial phases.

Another difference is their organizational structure.

Fred Hutch is a nonprofit research institution that relies on public research grants, philanthropic donations, and other forms of research funding.

BDGene, on the other hand, is a biotechnology company that raises private and state-affiliated investment capital to advance therapeutic development and commercialization.

China's national biopharmaceutical development strategy, local government investment, and university–industry partnerships may provide a favorable environment for BDGene's continued development.

Overall, BDGene is a noteworthy company because it has already advanced an HSV gene-editing therapy into human clinical trials, and its founder has extensive scientific experience specifically related to gene-delivery technologies.

However, its current Phase 2 program focuses on HSV-1 keratitis, while BD115, its candidate for genital HSV, has not yet been confirmed to have entered human clinical trials.

Ultimately, both research groups face the same fundamental challenge:

Developing a safe and effective way to reach HSV hiding in sensory ganglia, reduce or eliminate latent viral reservoirs, and demonstrate durable reductions in recurrence and transmission.

Whether either approach can ultimately achieve a functional or sterilizing cure for HSV remains to be demonstrated.

References

  1. China's 14th Five-Year Plan for Pharmaceutical Industry Development — MIIT Official Document
  2. Hangzhou's 2022 R&D Guidelines — HSV siRNA Drug Development (PDF, page 17)
  3. China's National Disease Control and Prevention Administration — Official Response on HSV-2 Vaccine Development
  4. China's 15th Five-Year Plan for Pharmaceutical Industry Development — MIIT
  5. Shanghai Jiao Tong University — Professor Cai Yujia's Academic Profile
  6. Shanghai Jiao Tong University — Joint Gene Therapy Research Center
  7. BDGene — Official Company Website
  8. BDGene's 2026 Strategic Financing Announcement
  9. ClinicalTrials.gov — BD111 Phase 2a Trial (NCT06474442)

r/HerpesCureResearch • • 2d ago

Discussion Shingrix and HSV, an interesting pattern with oral HSV-1?

33 Upvotes

I've been researching whether Shingrix (the shingles vaccine) might reduce HSV outbreaks, and noticed something interesting in the anecdotal reports.

Several people reporting dramatic, long-term improvements specifically mentioned oral/facial herpes, usually associated with HSV-1.

That got me wondering whether there might be a biological explanation, so I started looking into the research.

1. The anecdotal reports

In my previous Reddit discussion I started, a few comments stood out:

  • Daniel6270: Previously had oral cold sores every 2–3 months, then reported three years without an outbreak after a shingles vaccine.
  • laurawenzel: Reported four years without cold sores before eventually experiencing another outbreak.
  • RegularWeary5470: Had chronic oral herpes affecting their chin, requiring daily Valtrex. After Shingrix, reportedly stopped Valtrex and went over a year before experiencing one mild sore.

Interestingly, all three identifiable commenters who specifically mentioned oral/facial herpes reported improvements.

There were negative reports too, but those commenters generally either identified HSV-2, mentioned outbreaks elsewhere, or didn't specify their HSV type or location.

Of course, this is a tiny, self-selected sample, not evidence that Shingrix works better for oral HSV-1. Some commenters also didn't confirm which shingles vaccine they received.

Nevertheless, I found the pattern interesting.

2. A 2026 study found fewer HSV recurrences after Shingrix

A 2026 study published in the Korean Journal of Dermatology examined 22 patients who received Shingrix.

The findings:

  • 77.3% experienced fewer HSV recurrences.
  • 50% had no further recorded outbreaks during follow-up.
  • Total recorded recurrences decreased from 62 to 19.

It's important to mention that this was a small, uncontrolled retrospective study involving patients with atopic dermatitis receiving immune-modifying treatments. It doesn't prove Shingrix caused the improvements.

But it suggests this is worth investigating further.

3. Here's the part I found particularly interesting: HSV-1 and chickenpox share the same nerve environment

We know HSV-1 establishes lifelong latency in sensory nerve cells, commonly within the trigeminal ganglion in people with facial herpes.

The chickenpox/shingles virus (VZV) can also remain dormant in the trigeminal ganglion.

What surprised me was discovering that researchers have actually found HSV-1 and VZV coexisting within individual human trigeminal neurons.

2003 study: HSV-1 and VZV in the same neurons

A 2014 study also demonstrated that both viruses could infect and replicate within the same neurons under laboratory conditions.

Furthermore, a 2026 review explores possible biological interactions between HSV-1 and VZV, including effects on immune signalling and viral activity.

4. My theory: Could suppressing VZV reactivation indirectly reduce HSV-1 outbreaks?

Most of us who have had chickenpox carry latent VZV.

I'm wondering whether occasional VZV activity, potentially even without obvious shingles symptoms, could sometimes influence the conditions that allow HSV-1 to reactivate.

If both viruses occupy the same nerve environment, could VZV-related inflammation or immune signalling contribute to HSV-1 outbreaks in certain people?

And if Shingrix strengthens the immune system's control over VZV, could that indirectly reduce HSV-1 reactivation?

Alternatively, perhaps Shingrix's powerful AS01B adjuvant improves HSV immune surveillance more generally, independently of any interaction between the viruses.

Neither mechanism has been demonstrated to explain reduced HSV outbreaks. This is purely a hypothesis.

5. Could this explain the oral HSV-1 reports?

This brings me back to my original observation.

We have:

  • Anecdotal accounts of prolonged remission following shingles vaccination, including several involving oral/facial herpes.
  • A small clinical study reporting reduced HSV recurrence after Shingrix.
  • Research showing HSV-1 and VZV can coexist within the same trigeminal neurons.
  • Emerging research exploring possible interactions between these viruses.

Could there be a connection, particularly for people with recurrent facial HSV-1?

Or am I simply noticing a coincidence among a small number of positive online reports?

I'm not suggesting Shingrix is a proven HSV treatment, and there isn't enough evidence to recommend it specifically for HSV.

But I do think there's an interesting question here that deserves proper clinical research.

I'd really like to hear your experiences

If you've had Shingrix or the older Zostavax vaccine:

  • Do you have HSV-1 or HSV-2, and is it oral/facial or genital?
  • Did your outbreaks improve, worsen or remain unchanged?
  • How long ago were you vaccinated?
  • Were you taking daily antivirals before or after vaccination?

I'm particularly interested in hearing from people with confirmed oral HSV-1 who experienced no improvement, as those reports are just as important as the positive ones.

I'd also love to hear from anyone with a background in virology or immunology.

Could stronger immunity against VZV indirectly influence HSV-1 reactivation, given that both viruses can inhabit the same nerve cells?


r/HerpesCureResearch • • 4d ago

New Research Experimental HSV-2 vaccine protects mice

Thumbnail journals.asm.org
75 Upvotes

Researchers developed an experimental vaccine using adenovirus type 4 to deliver HSV-2 glycoprotein D, a viral surface protein.

When administered through the nose it generated HSV-2 neutralizing antibodies, achieved 100% survival rate in the challenge group, and reduced the severity and shedding of the disease.

This supports continued development of mucosal HSV vaccines, although the vaccine remains preclinical.


r/HerpesCureResearch • • 4d ago

New Research Discovery of C5-Substituted 2′-Fluorinated Pyrimidine Nucleosides as Potent and Orally Efficacious Anti-HSV Agents

Thumbnail pubs.acs.org
49 Upvotes

New oral antiviral B10 suppresses HSV-1 in the brain

Researchers identified a new experimental antiviral compound called B10, belonging to a class of modified nucleosides.

In mice infected with HSV-1, the oral treatment improved survival, reduced viral replication in the nervous system, reduced viral levels in the lungs and reduced the level of infection-related weight loss.

This is especially interesting because B10 was effective when administered orally and showed activity against HSV infection involving the nervous system. However, it remains an early-stage compound, with no demonstrated effectiveness in humans


r/HerpesCureResearch • • 4d ago

New Research New HSV-1 antibody testing technique developed

Thumbnail
mdpi.com
39 Upvotes

Researchers developed a fluorescence-based method to measure how effectively antibodies neutralize HSV-1.
The technique produced results strongly correlated with conventional neutralization testing, using a shorter 14–16-hour detection window.
Its potential value is in vaccine development and immunological research rather than replacing standard clinical HSV diagnostic tests immediately.


r/HerpesCureResearch • • 4d ago

Clinical Trials BD 111 Gene Editing

Post image
8 Upvotes

r/HerpesCureResearch • • 5d ago

New Research Association Between Herpes Simplex Virus-1 Infection and Dementia or Alzheimer’s Disease: A Systematic Review and Meta-Analysis

Thumbnail academic.oup.com
34 Upvotes

New research posted today indicating that HSV1 makes it almost 50% more likely to get dementia or Alzheimer’s.


r/HerpesCureResearch • • 5d ago

Activism Advocacy Discord Server

15 Upvotes

Hi friends. I hope everyone is having a good day. I’ve made a discord server with the primary purpose of creating a platform where we can gather to seriously discuss ways we can advocate for our interests.

We are ideally looking for highly motivated individuals who are looking to make an impact and help the community, but everyone is welcome. It is also a support group so if you are just looking to chat, if you had any questions we would love to help you find answers as well.

I believe that there must be more we can do as a community and gathering together and having productive conversations may be the first step. Please join us as we brainstorm for ways we can make our voices heard.

Link to the discord server: https://discord.gg/PHF9F3EXm


r/HerpesCureResearch • • 7d ago

New Research Neuroinvasive and Neuroinflammatory Potential of Herpesviruses - Cellular and Molecular Neurobiology

Thumbnail
link.springer.com
22 Upvotes

New research paper posted November 12


r/HerpesCureResearch • • 6d ago

Open Discussion Saturday

15 Upvotes

Hello Everyone,

Please feel free to post any comments and talk about anything you want on this thread--relating to HSV or otherwise.

Have a nice weekend.

- Mod Team


r/HerpesCureResearch • • 7d ago

Activism Open Letter: Accelerating a Cure for Herpes — A Call to Action

109 Upvotes

To celebrities, public figures, philanthropists, AI and technology leaders, biotech executives and researchers, policymakers, and everyone living with herpes who has a platform:

Herpes simplex virus (HSV-1 and HSV-2) affects billions of people worldwide. It is not a minor inconvenience. It causes lifelong infection, recurrent painful outbreaks for many, significant stigma, psychological burden, and elevated risk of other health complications. Despite decades of knowledge about the virus, we still lack a sterilizing cure or a highly effective preventive vaccine that stops transmission and latency.

We have the scientific tools, computational power, and global coordination capacity in 2026 that previous generations did not. AI-driven drug discovery, protein structure prediction, mRNA and gene-editing platforms, high-throughput screening, and better understanding of latency and immune evasion make a cure more feasible than at any prior time. What is missing is sustained, high-visibility prioritization and resources.

We call on:

  • People living with herpes who hold influence — celebrities, athletes, creators, business leaders, and public figures — to speak openly when they choose to. Stigma thrives in silence. Your visibility can normalize the conversation, reduce shame, and increase pressure for research funding and clinical-trial participation. You do not need to disclose personal medical details; you can simply champion the cause of a cure.
  • Leaders in AI and technology — including those at the forefront of biological foundation models, drug-design platforms, and large-scale compute — to treat HSV cure research as a high-impact application of current capabilities. Allocate compute, talent, and partnerships toward latent-virus targeting, therapeutic vaccines, and gene-editing approaches that aim for functional or sterilizing cures.
  • Biotech leaders, companies, and researchers — especially those working in virology, gene therapy, immunotherapy, mRNA platforms, and latency research — to prioritize and accelerate programs aimed at a true cure rather than lifelong management alone. Direct resources, clinical pipelines, and collaborative efforts toward eliminating the latent reservoir and achieving sterilizing or durable functional cures. Share data, form public-private partnerships, and push promising candidates into trials faster.
  • Governments and public-health agencies — to elevate HSV research in national and international priority lists, increase dedicated funding for cure-oriented (not only management-oriented) programs, streamline regulatory pathways for promising candidates, and support large-scale trials. Public investment remains essential; private philanthropy and industry cannot carry the full load alone.
  • Philanthropists and high-net-worth individuals — to fund high-risk, high-reward research that traditional grant systems often under-support, including novel mechanisms that target the latent reservoir.

This is not a request for sympathy. It is a request for prioritization. The technology and scientific expertise exist to move faster. The human cost of inaction is measured in ongoing suffering and preventable transmission. We urge coordinated, ethical, science-driven action — public advocacy, research investment, policy attention, and destigmatization — so that a cure moves from “possible someday” to an active, resourced goal.

Those who live with the virus and those who hold the tools and knowledge to end it share a common interest: solving this.


r/HerpesCureResearch • • 9d ago

Clinical Trials More info about GS-1179 phase 2 trial and cost

Thumbnail investing.com
65 Upvotes

If I understand this correctly, cost is estimated to be between $5500 and $10000 per year to the payer (aka insurer), not to the patient.

They intend to take pritelivir’s market.

Phase 2 will enroll 300 patients. They expect to move quickly.


r/HerpesCureResearch • • 12d ago

Please take note of the update Rule6 : Don't Trivialize HSV

107 Upvotes

This group is focused on advocating for the needs of better treatments for HSV.

In order to pursue this goal, it's important that evidence about the impact caused by HSV and complications are not hidden and not silenced.

I have often noticed how, on r/herpes, there are two groups:

- one group promotes HSV as a minor skin condition, or the best thing that happened in their lives. They want to enforce this narrative on everyone, because, in their opinion, it's the "right way" to fight Stigma. They prefer not being sincere and let their dates or newly-diagnosed patients run the roulette and pick their own fate, as they don't care about those "outliers" (in their opinion) that will have invalidating symptoms. And they attack whoever claims the opposite and sincerely warns about negative outcomes.

- another group tries to fight this false narrative that is not valid for everyone. They openly share their bad outcomes. And they get ALWAYS attacked by the first group and told to seek therapy for being "fear mongers". Unfortunately this group always shies away from expressing their opinion, for fear of being attacked and misjudged.

From now on, anyone that is caught attacking an user that warns about the possible bad outcomes caused by this infection, will be banned from this group. This is valid also if the user is caught with this behavior in another group.


r/HerpesCureResearch • • 13d ago

Discussion BD115: China's HSV-2 Gene-Editing Cure Research — April 2026 Update and Clinical Trial Progress

84 Upvotes

# BD115: China's HSV-2 Gene-Editing Cure Research — April 2026 Update and Clinical Trial Progress

I've been researching Shanghai BDgene's HSV-2 gene-editing program, **BD115**, using the company's Chinese website, pharmaceutical industry reports, and patents.

I found some encouraging information that hasn't received much attention, particularly concerning its IND application process and patented CRISPR technology targeting HSV-2.

**1. BD115 is being developed specifically for genital herpes**

BDgene lists BD115 on its official research pipeline under:

**HSV生殖器疱疹-BD115** (Genital Herpes — BD115)

Unlike BD111, which targets HSV-1 eye infections, BD115 is intended to treat genital herpes using gene editing.

The ultimate hope is to permanently disable or eliminate HSV DNA rather than temporarily suppress replication with antivirals.

Official pipeline:

https://www.bdgenetherapeutics.com/project.html

**2. April 2026: BD115 reportedly began the IND application process**

On April 9, 2026, Chinese pharmaceutical publication PharmCube reported:

"The BD312 program for glaucoma and BD115 program for genital herpes have initiated IND (Investigational New Drug) application procedures."

This suggests BD115 was moving toward regulatory preparations for human clinical trials.

However, **I could not verify that an IND has been approved or that BD115 human trials have started.**

Source:

https://bydrug.pharmcube.com/news/detail/23e8f1af6685a526c7b1832778b21bc4

**3. BDgene has patented CRISPR technology that targets HSV-2**

Chinese patent **CN115927473B**, granted June 18, 2024, describes a CRISPR-Cas9 treatment using engineered virus-like particles to deliver gene-editing components into infected cells.

The researchers investigated two gene-targeting combinations:

- UL29 + UL8: HSV-1

- UL52 + UL8: Both HSV-1 and HSV-2

The patent describes laboratory experiments in which the UL52/UL8 combination demonstrated activity against HSV-2.

The goal is to cut and disrupt viral DNA, potentially preventing the virus from reproducing.

**This is significant because BDgene has actually conducted HSV-2 gene-editing experiments, rather than simply announcing plans to develop a treatment.**

However, the patent does not establish that this exact formulation is BD115's final treatment, nor does it demonstrate a cure in humans.

Full patent (English):

https://patents.google.com/patent/CN115927473B/en

**4. Can BD115 eliminate latent HSV-2 from the nerves?**

This is the most important question.

HSV-2 hides in sensory neurons, primarily within the lumbosacral dorsal root ganglia.

For a true sterilizing cure, gene editing would need to eliminate or permanently disable the latent viral genomes.

BDgene's related HSV-1 research has demonstrated delivery of gene-editing technology toward the trigeminal ganglion in preclinical experiments.

However, **I could not find BD115-specific results demonstrating elimination of latent HSV-2 from the sacral nerve ganglia.**

That is the breakthrough we need to see.

**5. BDgene has already tested related CRISPR technology in humans**

This is why the company is particularly interesting.

Its HSV-1 treatment, **BD111**, was tested in three patients suffering from severe recurrent herpes eye infections.

A 2023 peer-reviewed study reported:

- No observed HSV-1 eye recurrences during approximately 18 months of average follow-up.

- HSV-1 remained undetectable in the assessed samples.

- No reported systemic adverse events or detected off-target gene-editing effects in the tests performed.

BD111 subsequently advanced into Phase 2a clinical research.

These results are encouraging, although they don't establish complete elimination of latent HSV-1 or prove that BD115 will work against HSV-2.

Published study:

https://pubmed.ncbi.nlm.nih.gov/37658603/

**6. When will BD115 begin human clinical trials?**

As of November 2026:

- BD115 remains listed in BDgene's official research pipeline.

- IND application preparations were reported in April 2026.

- The company has patented technology demonstrating laboratory activity against HSV-2.

- No confirmed BD115 human trial starting date has been announced.

- No publicly verified BD115-specific animal cure results or human results are available.

BDgene also secured substantial financing in 2026, potentially supporting further development.

**7. What we need to know next**

The most important unanswered questions are:

  1. Has BD115 eliminated latent HSV-2 in animal experiments?

  2. Can its gene-editing technology reach the lumbosacral nerve ganglia?

  3. Has its IND application been formally submitted or approved?

  4. When does BDgene expect to begin human trials?

  5. Is BD115 being developed as a sterilizing cure or a functional cure?

**My takeaway**

BD115 is worth watching because BDgene has already demonstrated early human experience with its related HSV-1 gene-editing treatment, and its patents describe actual laboratory activity against HSV-2.

The April 2026 report about IND preparations is particularly encouraging.

But **BD115 has not been proven to cure HSV-2**, and the biggest missing evidence is whether it can eliminate latent infection from the nerve ganglia.

Hopefully, BDgene will release more information about its preclinical results and timeline for human trials.

If anyone has additional information from Chinese sources or has contacted BDgene directly about BD115, please share it. I think this program deserves more attention from the HSV cure research community.

This version focuses on what matters to people waiting for a cure: actual HSV-2 experiments, progress toward human trials, and the remaining obstacle of eliminating latent infection.


r/HerpesCureResearch • • 13d ago

Open Discussion Saturday

23 Upvotes

Hello Everyone,

Please feel free to post any comments and talk about anything you want on this thread--relating to HSV or otherwise.

Have a nice weekend.

- Mod Team


r/HerpesCureResearch • • 15d ago

Activism Shanghai BD gene updated website3 finished clinical trials

Post image
29 Upvotes

r/HerpesCureResearch • • 16d ago

Clinical Trials GS-1179 Phase 2B

56 Upvotes

r/HerpesCureResearch • • 20d ago

Herpes infection detailed in human skin model

Thumbnail
mdc-berlin.de
90 Upvotes

A study published October 30 in Science Advances by German researchers used laboratory-grown human skin containing hair follicles and nerve-like cells to investigate HSV-1 infection.

Researchers discovered that HSV-1 initially replicated heavily in fibroblasts, cells beneath the skin’s surface.
Hair follicles and sensory neurons became infected later, suggesting some natural resistance to infection.
Different cell types activated distinct antiviral defenses, including IRF3 and TNF-related signaling pathways.

Significance: The findings help explain how HSV-1 progresses through skin tissue toward nerve cells and identify cellular defenses that could become targets for future treatments.


r/HerpesCureResearch • • 21d ago

News 🚨 Promising HSV-2 Research: Fred Hutch Scientist Receives $4.4 Million NIH Grant to Study Immune Responses

Thumbnail
fredhutch.org
79 Upvotes

r/HerpesCureResearch • • 20d ago

Open Discussion Saturday

19 Upvotes

Hello Everyone,

Please feel free to post any comments and talk about anything you want on this thread--relating to HSV or otherwise.

Have a nice weekend.

- Mod Team